Immunoassay Detects Severe Fever with Thrombocytopenia Syndrome Virus
|
By LabMedica International staff writers Posted on 25 Apr 2016 |

Image: A scanning electron micrograph (SEM) of severe fever with thrombocytopenia syndrome virus (Photo courtesy of the Japanese National Institute of Infectious Diseases).
Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne infectious disease with a high case fatality rate, and is caused by the SFTS virus (SFTSV) and the disease is endemic to China, South Korea, and Japan.
The viral ribonucleic acid (RNA) level in sera of patients with SFTS is known to be strongly associated with outcomes and therefore virological SFTS diagnosis with high sensitivity and specificity are required in disease endemic areas.
Scientists at the Japanese National Institute of Infectious Diseases (Tokyo, Japan) and their colleagues collected 63 serum samples from 55 acute phase patients suspected of SFTS in Japan. Viral gene detection by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) and viral antibody detection by immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) and/or indirect fluorescent antibody (IFA) were conducted to diagnose SFTS. From 55 patients, 34 of these were diagnosed as having SFTSV. Serum samples obtained from 18 healthy donors were used to establish the cut-off value of the IgG ELISA. Serum samples used for IgG ELISA were inactivated under the UV light in the biosafety cabinet for one hour.
The investigators generated novel monoclonal antibodies (MAbs) against the SFTSV nucleocapsid (N) protein and developed a sandwich antigen (Ag)-capture enzyme-linked immunosorbent assay (ELISA) for the detection of N protein of SFTSV using MAb and polyclonal antibody as capture and detection antibodies, respectively. The Ag-capture ELISAs were read using an optical density at 405 nm (OD405) was measured against a reference of 490 nm using a Model 680 Microplate Reader (Bio-Rad Laboratories Inc.; Hercules, CA, USA). The Ag-capture system was capable of detecting at least 350 to 1,220 50% Tissue Culture Infective Dose (TCID50)/100 μL/well from the culture supernatants of various SFTSV strains.
All 24 serum samples (100%) containing high copy numbers of viral RNA more than 105 copies/mL) showed a positive reaction in the Ag-capture ELISA, whereas 12 out of 15 serum samples (80%) containing low copy numbers of viral RNA (less than 105 copies/mL) showed a negative reaction in the Ag-capture ELISA. Among these Ag-capture ELISA- negative 12 samples, nine (75%) were positive for IgG antibodies against SFTSV. The authors conclude that the newly developed Ag-capture ELISA is useful for SFTS diagnosis in acute phase patients with high levels of viremia. The study was published on April 5, 2016, in the journal Public Library of Science Neglected Tropical Diseases.
The viral ribonucleic acid (RNA) level in sera of patients with SFTS is known to be strongly associated with outcomes and therefore virological SFTS diagnosis with high sensitivity and specificity are required in disease endemic areas.
Scientists at the Japanese National Institute of Infectious Diseases (Tokyo, Japan) and their colleagues collected 63 serum samples from 55 acute phase patients suspected of SFTS in Japan. Viral gene detection by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) and viral antibody detection by immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) and/or indirect fluorescent antibody (IFA) were conducted to diagnose SFTS. From 55 patients, 34 of these were diagnosed as having SFTSV. Serum samples obtained from 18 healthy donors were used to establish the cut-off value of the IgG ELISA. Serum samples used for IgG ELISA were inactivated under the UV light in the biosafety cabinet for one hour.
The investigators generated novel monoclonal antibodies (MAbs) against the SFTSV nucleocapsid (N) protein and developed a sandwich antigen (Ag)-capture enzyme-linked immunosorbent assay (ELISA) for the detection of N protein of SFTSV using MAb and polyclonal antibody as capture and detection antibodies, respectively. The Ag-capture ELISAs were read using an optical density at 405 nm (OD405) was measured against a reference of 490 nm using a Model 680 Microplate Reader (Bio-Rad Laboratories Inc.; Hercules, CA, USA). The Ag-capture system was capable of detecting at least 350 to 1,220 50% Tissue Culture Infective Dose (TCID50)/100 μL/well from the culture supernatants of various SFTSV strains.
All 24 serum samples (100%) containing high copy numbers of viral RNA more than 105 copies/mL) showed a positive reaction in the Ag-capture ELISA, whereas 12 out of 15 serum samples (80%) containing low copy numbers of viral RNA (less than 105 copies/mL) showed a negative reaction in the Ag-capture ELISA. Among these Ag-capture ELISA- negative 12 samples, nine (75%) were positive for IgG antibodies against SFTSV. The authors conclude that the newly developed Ag-capture ELISA is useful for SFTS diagnosis in acute phase patients with high levels of viremia. The study was published on April 5, 2016, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Japanese National Institute of Infectious Diseases
Bio-Rad Laboratories
Latest Microbiology News
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
Channels
Clinical Chemistry
view channel
Blood Test Tracks Transplant Health Using Donor DNA
Organ transplantation offers life-saving treatment for patients with end-stage disease, but complications such as rejection remain a constant risk. Monitoring transplanted organs typically relies on invasive... Read more
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Dementia in Women 25 Years Before Symptoms Begin
Dementia and Alzheimer’s disease often develop silently over many years before symptoms appear. Detecting risk earlier could allow preventive strategies to begin long before memory problems interfere with... Read more
Serial Liquid Biopsies Reveal Therapy Resistance in Metastatic Prostate Cancer
Metastatic Prostate cancer can rapidly adapt under treatment, making it difficult to detect resistance before clinical progression. Genomic results from archival tumor tissue may no longer reflect the... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreMicrobiology
view channel
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more








